The prevalence of nasal polyps and the corresponding urinary LTE 4 levels in severe compared to mild and moderate asthma

European Annals of Allergy and Clinical Immunology

Volumn 42, Issue 3, 2010, Pages 120-124

  Micheletto, C ^a   Visconti, M ^a   Trevisan, F ^a   Tognella, S ^a   Bertacco, S ^a   Dal Negro, R W ^a  

^a Bussolengo Gen Hospital   (Italy)

Author keywords

Asa intolerance; Cysteinil leukotrienes; Nasal polyps; Severe asthma

Indexed keywords

ACETYLSALICYLIC ACID; LEUKOTRIENE E4;

ADULT; AGED; ARTICLE; ASTHMA; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; ENDOSCOPY; ENZYME IMMUNOASSAY; FEMALE; HUMAN; MALE; NOSE POLYP; PREVALENCE; URINE LEVEL;

ADOLESCENT; ADULT; AGED; ASPIRIN; ASTHMA; COHORT STUDIES; FEMALE; HUMANS; LEUKOTRIENE E4; MALE; MIDDLE AGED; NASAL POLYPS; PREVALENCE;

EID: 77953906201     PISSN: 03979148     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Bateman ED, Hurd SS, Barnes PJ, et al. Global strategy for asthma management and prevention: GINA executive summary. Eur Resp J 2008; 31: 143-78.
2. Wenzel S, Szefler SJ. Managing severe asthma. J Allergy Clin Immunol 2006; 117: 508-11.
3. Dal Negro RW, Micheletto C, Tosatto R, Dionisi M, Turco P, Donner CF. Costs of asthma in Italy: results of the SIRIO (Social Impact of Respiratory Integrated Outcomes) study. Respir Med 2007; 101: 2511-9. (Pubitemid 47618389)
4. Chung KF, Godard P, Adelroth E, et al. Difficult/therapy-resistant asthma: the need for an integrated approach to define clinical phenotypes, evaluate risk factors, understand patophysiology and find novel therapies. ERS task force on Difficult/Therapy Resistant Asthma. Eur Resp J 1999; 13: 1198-208.
5. Durham SR, Mackay LS. Diseases of the nose. In: Gibson GJ, Geddes DM, Costabel U, Sterk PJ, Corrin B (Eds). Respiratory Medicine, 3rd edn. Saunders, London, 2003; 1035-47.
6. Scadding GK, Durham SR, Mirakian R, et al. BSACI guidelines for the management of rhinosinusitis and nasal polyposis. Clin Exp Allergy 2007; 38: 260-75.
7. Lewis RA, Austen KF, Soberman RJ. Leukotrienes and other products of the 5-lipoxigenase pathway. N Eng J Med 1990; 323: 645-55.
8. Manning PJ, Rokach J,Malo JL, et al. Urinary leukotriene E4 levels during early and late asthmatic response. J Allergy Clin Immunol 1990; 86: 211-20.
9. Stevenson DD, Szczeklik A. Clinical and pathologic perspectives on aspirin sensitivity and asthma. J Allergy Clin Immunol 2006; 118: 773-86. (Pubitemid 44515109)
10. Pérez-Novo CA, Claeys C, Van Cauwenberge P, Bachert C. Expression of eicosanoid receptors subtypes and eosinophilic inflammation: implication on chronic rhinosonusitis. Respir Res 2006; 7: 75. (Pubitemid 43959903)
11. Higashi N, Taniguchi M,Mita H, et al. Clinical features of asthmatic patients with increased urinary leukotriene E4 exctretion: involvement of chronic hyperplastic rhinosinusitis with nasal polyposis. J Allergy Clin Immunol 2004; 113: 277-83.
12. 4 excretion: a study vs AIA without polyps, mild atopic asthma, and normal controls. Eur Ann Allergy Clin Immunol 2006; 38: 20-3.
13. Newton JR, Ah-See KW. A review of nasal polyposis. Ther Clin Risk Manag 2008; 4 (2): 507-12.
14. Fokkens WJ, Lund VJ, Mullol J. European Position Paper on Rhinosinusitis and Nasal Polyposis. Rhinology 2007; 45 (Suppl. 20): 1-139.
15. Pradelles P, Grassi J, Maclouf JA. Enzyme immunoassays of ecosanoids using acetylcholinesterase as label : an alternative to radioimmunoassay. Anal Chem 1985; 57: 1170-3.
16. Sampson AP, Pizzichini E, Bisgaard H. Effects of cysteinyl leukotrienes and leukotriene receptor antagonists on markers of inflammation. J Allergy Clin Immunol 2003; 111 (suppl): S49-61.
17. Casadevall J, Ventura P-J,Mullol J, Picado C. Intranasal challenge with aspirin in the diagnosis of aspirin intolerant asthma: evaluation of nasal response by acoustic rhinometry. Thorax 2000; 55: 921-4.
18. Lai V, Corey J. The use of acoustic rhinometry to quantitatively assess changes after intranasal allergen challenge. Am J Rhinology 1994; 8: 171-3.
19. Taylor DR, Bateman ED, Boulet L-P, Boushey HA, Busse WW. A new perspective on concepts of asthma severità and control. Eur Resp J 2008; 32: 545-54.
20. Sanak M, Pierzchalska M, Bazan-Socha S, Szczeklik A. Enhanced expression of the leukotriene C4 synthase due to overactive transcription of an allelic variant associated with aspirin-intolerant asthma. Am J Respir Cell Mol Biol. 2000; 23: 290-6.
21. Micheletto C, Tognella S, Visconti M, Trevisan F, Dal Negro RW. Changes in urinary LTE4 and nasal functions following nasal provocation test with ASA in ASA-tolerant and - intolerant asthmatics. Resp Med 2006; 100: 2144-50. (Pubitemid 44718396)
22. Figueroa DJ, Breyer RM, Defoe SK. Expression of the cysteinyl leukotriene1 receptor in normal human lung and periferal blood leukocytes. Am Rev Respir Crit Care Med 2001; 163: 226-33.
23. Nicosia S, Capra V, Rovati GE. Leukotrienes as mediator of asthma. Pulm Pharmacol Ther 2001; 14: 3-19.
24. Obase Y, Shimoda T, Tomari S, et al. Effects of Pranlukast on chemical mediators in induced sputum on provocation tests in atopic and aspirin-intolerant asthmatics patients. Chest 2002; 121: 143-50. (Pubitemid 34114239)
25. Lee DKC, Haggart K, Robb FM, Lipworth BJ. Montelukast protects against nasal lysine-aspirin challenge in patients with aspirin-induced asthma. Eur Resp J 2004; 24: 226-30. (Pubitemid 39139789)
26. Sousa AR, Parikh A, Scadding G, Corrigan CJ, Lee TH. Leukotriene-receptor expresson on nasal mucosal inflammatory cells in aspirin-sensitive rhinosinusitis. N Engl J Med 2002; 347: 1493-9. (Pubitemid 35257588)
27. Micheletto C, Tognella S, Visconti M, Pomari C, Trevisan F, Dal Negro RW. Montelukast 10 mg improves nasal function and nasal response to aspirin in ASA-sensitive asthmatics: a controlled study vs placebo. Allergy 2004; 59: 289-94.